Welcome

PharmaSea brings together a broad international, interdisciplinary consortium of 24 partners from 13 countries from industry, academia and non-profit organisations with world-leading researchers in the areas of marine genomics, biosynthesis and chemical structure analysis as well as legal experts. The PharmaSea project focuses on biodiscovery research and the development and commercialisation of new substances from marine organisms. Its primary goal is to collect samples from some of the hottest, deepest and coldest places on the planet. These samples will be screened to uncover marine microbes and new bioactive compounds to evaluate their potential as novel drug leads, antibiotics or ingredients for nutrition or cosmetic applications. PharmaSea is funded by the European Union under its FP7 programme.

News

  • US tasks Basilea with antibiotics launch

    US tasks Basilea with antibiotics launch

    25.04.2016 - The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available. More

  • How to conserve and sustainably manage biodiversity in the high seas?

    How to conserve and sustainably manage biodiversity in the high seas?

    20.04.2016 - Marine Areas Beyond National Jurisdiction (ABNJ) are commonly referred to as the high seas. The high seas are biodiversity-rich and complex ecosystems that make up 40 % of the surface of the planet and are not controlled by one single nation. Often they are regarded as the world’s last global common. More

  • What’s new with the Nagoya Protocol?

    What’s new with the Nagoya Protocol?

    24.03.2016 - One of the overarching goals of the Convention on Biological Diversity (CBD) is the fair distribution of advantages that arise from the utilisation of genetic resources. More

Executive Committee

Institutions

Calendar

All events